Attributes | Values |
---|
rdf:type
| |
description
| - wetenschappelijk artikel (nl)
- artículu científicu espublizáu en xineru de 2020 (ast)
- article scientifique publié en 2020 (fr)
- scientific article published on 22 January 2020 (en)
- наукова стаття, опублікована 22 січня 2020 (uk)
- գիտական հոդված հրատարակված 2020 թվականի հունվարի 22-ին (hy)
|
publication date
| |
publication date
| |
author name string
| |
author name string
| - Martijn W Heymans
- Kodandaram Pillarisetti
- Amy Axel
- Bhavesh Vaidya
- Berris van Kessel
- Rengasamy Boominathan
- Jocelyn Sendecki
- Christie P M Verkleij
- Francois Gaudet
- Jhon A Marin Soto
- Lisa C Holthof
- Marloes E C Broekmans
|
rdfs:label
| - Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab (en)
- Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab (nl)
|
skos:prefLabel
| - Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab (en)
- Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab (nl)
|
name
| - Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab (en)
- Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab (nl)
|
author
| |
author
| |
title
| |
title
| - Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab (en)
|
instance of
| |
instance of
| |
PubMed ID
| |
PubMed ID
| |
PubMed ID
| |
published in
| |
published in
| |
DOI
| |
DOI
| |
DOI
| - 10.1158/1078-0432.CCR-19-2299
|
is about
of | |
is cites work
of | |
is cites work
of | |